Subscribe for TO2 warrants agreement-svg More information More about resistance Cancer drug resistance Pipeline Pipeline Financial reports Financial Reports PRESS RELEASES 5 November 2024 Invitation to Scandion Oncology webcast and conference call November 11, 2024 Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will publish its Q3 2024 interim report on Monday November 11, 2024, before 09:00 CET. Scandion’s Executive Management will host a webcast and conference call the same day at 09:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event can be obtained as follows: LIVE access on Monday November 11, 2024, at 09.00 CET: https://financialhearings.com/event/48943 REPLAY accessWebcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com For further information please contact:Johnny Stilou, CFOPhone: +45 2960 3532E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on November 5, 2024, at 17.00 CET. About Scandion Oncology Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market AttachmentsInvitation To Scandion Oncology Webcast And Conference Call Q3 2024 Invitation To Scandion Oncology Webcast And Conference Call Q3 2024 4 November 2024 Scandion Oncology announces the start of the exercise period for warrants of series TO 2 Scandion Oncology ("Scandion" or the "Company") announces that the exercise period for the warrants of series TO 2, which were issued in connection with the Company's rights issues of units during the second quarter of 2024, begins today on 4 November 2024. Note that warrants of series TO 2 not sold by 14 November 2024 or used to subscribe for shares no later than on 18 November 2024, expire without value. Scandion carried out a rights issue of units during the second quarter of 2024. Within the rights issue, a total of 143,416,179 warrants of series TO 2 were issued. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 2 shall correspond to seventy (70) per cent of the volume weighted average price of the Company’s share during the period from and including 16 October 2024 up to and including 29 October 2024, however not lower than the quota value of the share and not higher than 125 per cent of the subscription price in the rights issue. During the measurement period, the volume-weighted average price for the Company's share was approximately SEK 0,12, therefore the exercise price for the warrants of series TO 2 has been determined to SEK 0,12. Subscription of shares by exercise of warrants of series TO 2 will take place during the period from and including 4 November 2024 up to and including 18 November 2024. If all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 18 November 2024 or sell the warrants no later than on 14 November 2024. Please observe that certain nominees might close their subscription earlier than on 18 November 2024. If all warrants of series TO 2 are exercised the share capital will increase with DKK 10,541,089.15650 through the issuance of 143,416,179 new shares. This correspondence to a dilution effect of approximately 38,2 per cent of the number of shares and number of votes. Full terms and conditions regarding the warrants of series TO 2 and information about the Company is available in the prospectus which was approved by the Danish Financial Supervisory Authority (the "DFSA") […] 31 October 2024 Correction: Scandion Oncology announces exercise price for warrants of series TO 2 On Wednesday 30 October 2024, Scandion Oncology issued a release mistakenly stating that the exercise price for warrants of series TO 2 would be SEK 0.11. The correct exercise price is SEK 0.12 as SEK 0.11 would result in an exercise price lower than the quota value of the share. As a result, if all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs rather than the previously stated SEK 15,8 million. The corrected press release is provided in full below. Scandion Oncology announces exercise price for warrants of series TO 2 Scandion Oncology ("Scandion" or the "Company") announces that the exercise price for the warrants of series TO 2 has been determined to SEK 0,12 and that the exercise period starts on 4 November 2024. Scandion carried out a rights issue of units during the second quarter of 2024. Within the rights issue, a total of 143,416,179 warrants of series TO 2 were issued. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 2 shall correspond to seventy (70) per cent of the volume weighted average price of the Company’s share during the period from and including 16 October 2024 up to and including 29 October 2024, however not lower than the quota value of the share and not higher than 125 per cent of the subscription price in the rights issue. During the measurement period, the volume-weighted average price for the Company's share was approximately SEK 0,12, therefore the exercise price for the warrants of series TO 2 has been determined to SEK 0,12. Subscription of shares by exercise of warrants of series TO 2 will take place during the period from and including 4 November 2024 up to and including 18 November 2024. If all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 18 November 2024 or sell the warrants no later than on 14 November 2024. Please observe that certain nominees might close their subscription earlier than on 18 November 2024. If all warrants of series TO 2 are exercised the share […] All Press Releases UPCOMING EVENTS 2024-11-11 Q3 report 2024 2025-02-28 Year-end report 2024 View all upcoming events Learn more about our unique first-in-class lead compound SCO-101 Watch the interview here: Part 1 / Part 2 / Part 3Read more about SCO-101 Annual General Meeting Scandion Oncology Annual General Meeting on May 6 at 14.00Read more LATEST PRESENTATIONS 22 May 2024 KOL interview on CORIST – Professor Josep Tabernero, MD, PhD Read more about the presentation here. 16 May 2024 R&D Update May 15 Watch the R&D Update from May 15th 4 March 2024 BioStock interview w. Francois Martelet Our clinical study and partnering strategy are jointly progressing. View all presentations A great place to work For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatmentsRead more